Daunorubicin\/cytarabine is a fixed-dose combination medication used for the treatment of acute myeloid leukemia. It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.<\/p>\n
If Daunorubicin and cytarabine liposome injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n","protected":false},"excerpt":{"rendered":"
Daunorubicin and cytarabine\u00a0 is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).<\/p>\n
Approval Date:<\/strong> 2017 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cDaunorubicin and cytarabine liposome injection\u201d based on the information you provide.<\/p>\n
\nProprietary Name:<\/strong> On Request
\nActive Ingredient(s):<\/strong> Daunorubicin and cytarabine liposome injection
\nDosage Forms And Strengths:<\/strong>
\nManufacturer:<\/strong>
\nMedicine Approved By: –<\/strong> European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:\u00a0<\/strong>Click Here
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n